Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
33.19
USD
|
-3.35%
|
|
-1.04%
|
+49.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,265
|
3,001
|
1,785
|
1,543
|
1,245
|
1,884
|
-
|
-
|
Enterprise Value (EV)
1 |
3,184
|
2,690
|
1,582
|
1,421
|
1,215
|
1,808
|
1,869
|
1,658
|
P/E ratio
|
-6.96
x
|
-9.14
x
|
1.24
x
|
-6.64
x
|
-3.52
x
|
-7.34
x
|
-5.93
x
|
-7.75
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
27.7
x
|
14.8
x
|
-
|
108
x
|
46.4
x
|
44
x
|
16.5
x
|
9.35
x
|
EV / Revenue
|
27
x
|
13.2
x
|
-
|
99.8
x
|
45.3
x
|
42.2
x
|
16.4
x
|
8.23
x
|
EV / EBITDA
|
-7.61
x
|
-8.79
x
|
-4.29
x
|
-3.73
x
|
-3.16
x
|
-4.55
x
|
-4.77
x
|
-5.19
x
|
EV / FCF
|
-8.32
x
|
-8.8
x
|
-3.83
x
|
-4.52
x
|
-4.09
x
|
-5.65
x
|
-7.88
x
|
-7.39
x
|
FCF Yield
|
-12%
|
-11.4%
|
-26.1%
|
-22.1%
|
-24.5%
|
-17.7%
|
-12.7%
|
-13.5%
|
Price to Book
|
4.47
x
|
7.48
x
|
1.54
x
|
1.4
x
|
1.53
x
|
2.66
x
|
2.9
x
|
3.59
x
|
Nbr of stocks (in thousands)
|
68,371
|
69,260
|
54,308
|
54,945
|
55,891
|
56,773
|
-
|
-
|
Reference price
2 |
47.75
|
43.33
|
32.87
|
28.08
|
22.27
|
33.19
|
33.19
|
33.19
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
117.9
|
203.2
|
-
|
14.24
|
26.82
|
42.79
|
114.1
|
201.5
|
EBITDA
1 |
-418.2
|
-306.2
|
-369.2
|
-380.5
|
-384.9
|
-397.4
|
-391.8
|
-319.6
|
EBIT
1 |
-426.3
|
-316.1
|
-378.4
|
-389
|
-391.5
|
-391.3
|
-361.8
|
-302.6
|
Operating Margin
|
-361.57%
|
-155.59%
|
-
|
-2,732.07%
|
-1,459.52%
|
-914.37%
|
-317.08%
|
-150.21%
|
Earnings before Tax (EBT)
1 |
-411.5
|
-327.4
|
-356.5
|
-231.8
|
-352.1
|
-251.6
|
-316.5
|
-250.1
|
Net income
1 |
-411.5
|
-327.4
|
1,605
|
-231.8
|
-352.1
|
-262.6
|
-344.7
|
-285.6
|
Net margin
|
-348.97%
|
-161.11%
|
-
|
-1,627.82%
|
-1,312.63%
|
-613.61%
|
-302.11%
|
-141.79%
|
EPS
2 |
-6.860
|
-4.740
|
26.55
|
-4.230
|
-6.330
|
-4.519
|
-5.594
|
-4.283
|
Free Cash Flow
1 |
-382.8
|
-305.7
|
-413.1
|
-314.4
|
-297.1
|
-319.9
|
-237.2
|
-224.4
|
FCF margin
|
-324.64%
|
-150.43%
|
-
|
-2,207.58%
|
-1,107.49%
|
-747.56%
|
-207.89%
|
-111.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
0.832
|
5.582
|
3.516
|
4.31
|
5.609
|
6.712
|
7.399
|
7.103
|
8.189
|
9.518
|
11.26
|
34.63
|
21.19
|
24.7
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-88.82
|
-91.89
|
-
|
-104.9
|
-90.72
|
-99
|
-100
|
100
|
-
|
-
|
EBIT
1 |
-104.8
|
-101.1
|
-97.64
|
-91.09
|
-99.17
|
-90.61
|
-93.7
|
-100.9
|
-106.3
|
-92.07
|
-98.1
|
-98.74
|
-77.35
|
-92.87
|
-80.89
|
Operating Margin
|
-
|
-12,156.85%
|
-1,749.19%
|
-2,590.73%
|
-2,300.97%
|
-1,615.49%
|
-1,396.01%
|
-1,363.66%
|
-1,496.23%
|
-1,124.34%
|
-1,030.66%
|
-876.81%
|
-223.39%
|
-438.19%
|
-327.48%
|
Earnings before Tax (EBT)
1 |
-98.58
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-81.55
|
-90.19
|
-57.71
|
-2.829
|
-77.55
|
-75.5
|
Net income
1 |
-94.63
|
-94.77
|
-91.81
|
-81.75
|
36.53
|
-81.02
|
-83.81
|
-91.32
|
-95.94
|
-81.55
|
-92.47
|
-43.11
|
-29.3
|
-77.55
|
-75.5
|
Net margin
|
-
|
-11,391.11%
|
-1,644.68%
|
-2,325%
|
847.47%
|
-1,444.43%
|
-1,248.6%
|
-1,234.27%
|
-1,350.7%
|
-995.84%
|
-971.47%
|
-382.86%
|
-84.61%
|
-365.9%
|
-305.64%
|
EPS
2 |
-1.740
|
-1.740
|
-1.680
|
-1.490
|
0.6700
|
-1.470
|
-1.510
|
-1.640
|
-1.720
|
-1.450
|
-1.601
|
-0.8732
|
-0.6375
|
-1.530
|
-1.315
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
80.9
|
311
|
203
|
122
|
30.1
|
76.8
|
15.4
|
226
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-383
|
-306
|
-413
|
-314
|
-297
|
-320
|
-237
|
-224
|
ROE (net income / shareholders' equity)
|
-62%
|
-63%
|
190%
|
-19.4%
|
-36.8%
|
-61.6%
|
-43.4%
|
-26.5%
|
ROA (Net income/ Total Assets)
|
-47%
|
-37.5%
|
140%
|
-17.3%
|
-32.4%
|
-17.9%
|
-36.7%
|
-22.4%
|
Assets
1 |
874.6
|
871.8
|
1,145
|
1,338
|
1,088
|
1,467
|
938.7
|
1,277
|
Book Value Per Share
2 |
10.70
|
5.790
|
21.40
|
20.10
|
14.60
|
12.50
|
11.40
|
9.250
|
Cash Flow per Share
2 |
-
|
-
|
-6.740
|
-5.650
|
-5.320
|
-4.620
|
-4.510
|
-
|
Capex
1 |
12.2
|
14.9
|
5.74
|
4.88
|
1
|
3.97
|
5.6
|
10.4
|
Capex / Sales
|
10.32%
|
7.34%
|
-
|
34.28%
|
3.72%
|
9.27%
|
4.91%
|
5.14%
|
Announcement Date
|
2/13/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
33.19
USD Average target price
41.67
USD Spread / Average Target +25.54% Consensus |
1st Jan change
|
Capi.
|
---|
| +49.03% | 1.88B | | +9.58% | 115B | | +12.41% | 107B | | -3.32% | 21.6B | | -12.38% | 22.31B | | -6.45% | 19.19B | | -3.35% | 18.23B | | -38.57% | 17.62B | | +7.51% | 14.26B | | +35.67% | 12.37B |
Bio Therapeutic Drugs
|